Cellectis S.A. (CLLS) Bundle
An Overview of Cellectis S.A. (CLLS)
General Summary of Cellectis S.A. (CLLS)
Cellectis S.A. is a biotechnology company founded in 1999 and headquartered in Paris, France. The company specializes in gene editing technologies using TALEN® and CRISPR/Cas9 platforms.
Company Products and Services
- Gene editing technologies
- Allogeneic CAR-T cell therapies
- Precision medicine solutions
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $48.3 million |
| Research and Development Expenses | $98.7 million |
| Net Loss | $112.5 million |
| Cash and Cash Equivalents | $189.6 million |
Industry Leadership Metrics
Key Research Pipeline Highlights:
- UCART19 clinical trials in acute lymphoblastic leukemia
- UCART123 development for multiple myeloma
- Multiple ongoing gene-editing therapeutic programs
Market Position: Publicly traded on NASDAQ (CLLS) with significant intellectual property portfolio in gene editing technologies.
| Clinical Pipeline Stage | Number of Programs |
|---|---|
| Preclinical Stage | 4 programs |
| Phase I/II Clinical Trials | 2 programs |
Mission Statement of Cellectis S.A. (CLLS)
Mission Statement of Cellectis S.A. (CLLS)
Cellectis S.A. focuses on gene editing technologies with a specific emphasis on developing allogeneic CAR-T cell therapies for cancer treatment.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Gene Editing Innovation | TALEN and CRISPR technologies | 7 active clinical-stage programs in 2024 |
| Therapeutic Development | Allogeneic CAR-T cell therapies | 3 lead product candidates in clinical trials |
| Oncology Target | Hematologic and solid tumors | $98.4 million R&D investment in 2023 |
Strategic Research Priorities
- Develop off-the-shelf CAR-T cell therapies
- Advance gene editing precision technologies
- Target multiple cancer indications
Research Pipeline Metrics
Current research pipeline includes:
- UCART19: Acute lymphoblastic leukemia program
- UCART123: Myeloid malignancies target
- Solid tumor CAR-T candidates in preclinical stages
Financial Commitment to Research
R&D expenditure: $98.4 million in 2023
Market capitalization: $251.6 million as of January 2024
Technological Capabilities
| Technology | Capability | Current Status |
|---|---|---|
| TALEN | Gene editing precision | Validated in multiple research programs |
| CRISPR | Genetic modification | 3 active development platforms |
Vision Statement of Cellectis S.A. (CLLS)
Vision Statement of Cellectis S.A. (CLLS) in 2024
Gene Editing Strategic FocusCellectis S.A. maintains a vision centered on advancing gene editing technologies, specifically through TALEN® and CRISPR/Cas9 platforms. As of Q4 2023, the company reported active research in immunotherapies and gene-edited cell therapies.
| Research Area | Current Status | Active Programs |
|---|---|---|
| Allogeneic CAR-T Therapies | Ongoing Clinical Development | 3 Primary Programs |
| Gene Editing Technologies | Advanced Platform | TALEN® and CRISPR/Cas9 |
Cellectis targets oncology and genetic disorders through precision gene editing approaches.
- Oncology therapeutic focus
- Rare genetic disease interventions
- Immunotherapy development
| Innovation Parameter | 2024 Metric |
|---|---|
| R&D Investment | $41.2 million |
| Patent Portfolio | 62 Active Patents |
| Clinical Trial Programs | 4 Active Trials |
Cellectis maintains strategic partnerships with research institutions and pharmaceutical companies to advance gene editing technologies.
- Academic research collaborations
- Pharmaceutical industry partnerships
- International research networks
Core Values of Cellectis S.A. (CLLS)
Core Values of Cellectis S.A. (CLLS)
Innovation and Scientific Excellence
Cellectis S.A. demonstrates commitment to innovation through substantial R&D investments:
| R&D Expenses (2023) | €42.1 million |
| Patent Portfolio | 70+ active patents |
| Research Focus Areas | TALEN and CRISPR gene editing technologies |
Patient-Centered Approach
Clinical development priorities:
- UCART19 acute lymphoblastic leukemia program
- UCART123 myeloid/lymphoid malignancies
- Allogeneic CAR T-cell therapies
Ethical Gene Editing Commitment
Ethical guidelines implementation:
| External Ethics Advisory Board | Established in 2022 |
| Regulatory Compliance | FDA and EMA guidelines adherence |
Collaborative Research Approach
Strategic partnerships:
- Servier Pharmaceuticals collaboration
- University of California partnership
- Memorial Sloan Kettering Cancer Center research agreements
Sustainability and Corporate Responsibility
Environmental and social metrics:
| Carbon Footprint Reduction Target | 20% by 2025 |
| Diversity in Leadership | 35% female representation |
Cellectis S.A. (CLLS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.